Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets.

[1]  C. Marsden,et al.  Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP , 1989, Neuroscience Letters.

[2]  W. Gibb,et al.  The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine , 1989, Movement disorders : official journal of the Movement Disorder Society.

[3]  Eminy H Y Lee.  Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on striatal biopterin in BALB/c mice , 1988, Neuroscience Letters.

[4]  D. German,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost? , 1988, Neuroscience.

[5]  C. Marsden,et al.  An immunohistochemical study of the acute and long-term effects of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in the marmoset , 1987, Neuroscience.

[6]  Effects of dopamine metabolism of MPTP and MPP+ infused through a push-pull cannula into the caudate nucleus of awake adult male rats , 1987, Brain Research.

[7]  R. Roth,et al.  Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF , 1987, Brain Research.

[8]  C. Markham,et al.  Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP , 1987, Brain Research.

[9]  H. Kimura,et al.  Reversible serotoninergic neurotoxicity ofN-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse striatum studied by neurochemical and immunohistochemical approaches , 1987, Brain Research.

[10]  J W Langston,et al.  Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys , 1986, Annals of neurology.

[11]  T. Paolo,et al.  Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys , 1986, Brain Research.

[12]  B. A. Brooks,et al.  Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys , 1986, Neuroscience.

[13]  T. Nagatsu,et al.  Early and late effects of systemically administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on tyrosine hydroxylase activity in vitro and on tyrosine hydroxylation in tissue slices of mouse striatum , 1986, Neuroscience Letters.

[14]  D. Price,et al.  Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A tyrosine hydroxylase immunocytochemical study in monkey , 1986, Neuroscience.

[15]  I. Mitchell,et al.  Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus , 1985, Neuroscience Letters.

[16]  W. Schultz,et al.  Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism , 1985, Neuroscience Letters.

[17]  T. Nagatsu,et al.  Inhibition of tyrosine hydroxylation in rat striatal tissue slices by 1-methyl-4-phenylpyridinium ion , 1985, Neuroscience Letters.

[18]  B. Bioulac,et al.  MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study , 1985, Brain Research.

[19]  C. Marsden,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset , 1984, Neuroscience Letters.

[20]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[21]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.